Announces Pricing of Underwritten Public Offering of Common Stock and Warrants
Summary
6105, or by email at syndicate@leerink.com.This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company committed to developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. Vincerx has assembled a seasoned management team with a proven track record of successful oncology drug development, approvals, and value creation. Vincerxs diverse pipeline consists of the next-generation antibody-drug conjugate, VIP943, in Phase 1; small molecule-drug conjugate, VIP236, in Phase 1; preclinical antibody-drug conjugate, VIP924; CDK9 inhibitor, enitociclib, in an NIH-sponsored Phase 1; and VersAptx, its versatile and adaptable, next-generation bioconjugation platform.Vincerx is based in Palo Alto, California, and has a research facility in Monheim, Germany.This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as those, among others, relating to Vincerxs expectations regarding the completion, timing and size of the public offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by Vincerx is contained in the section captioned Risk Factors in the prospectus supplement related to the public offering and are detailed from time to time in Vincerxs periodic reports filed with the SEC, including its most recent Annual Report on Form 10-K. Vincerx disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.